JPWO2020238998A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020238998A5 JPWO2020238998A5 JP2021569941A JP2021569941A JPWO2020238998A5 JP WO2020238998 A5 JPWO2020238998 A5 JP WO2020238998A5 JP 2021569941 A JP2021569941 A JP 2021569941A JP 2021569941 A JP2021569941 A JP 2021569941A JP WO2020238998 A5 JPWO2020238998 A5 JP WO2020238998A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- set forth
- chain variable
- variable region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims 17
- 125000003275 alpha amino acid group Chemical group 0.000 claims 17
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 claims 16
- 239000000427 antigen Substances 0.000 claims 9
- 102000036639 antigens Human genes 0.000 claims 9
- 108091007433 antigens Proteins 0.000 claims 9
- 239000012634 fragment Substances 0.000 claims 9
- 102000039446 nucleic acids Human genes 0.000 claims 5
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- 108020004707 nucleic acids Proteins 0.000 claims 5
- 206010016654 Fibrosis Diseases 0.000 claims 4
- 101150111783 NTRK1 gene Proteins 0.000 claims 4
- 210000003719 b-lymphocyte Anatomy 0.000 claims 4
- 230000004761 fibrosis Effects 0.000 claims 4
- 230000035772 mutation Effects 0.000 claims 4
- 239000002773 nucleotide Substances 0.000 claims 4
- 125000003729 nucleotide group Chemical group 0.000 claims 4
- 208000002193 Pain Diseases 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 2
- 208000005615 Interstitial Cystitis Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 230000037430 deletion Effects 0.000 claims 2
- 238000012217 deletion Methods 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 101710187798 60S ribosomal protein L23 Proteins 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000010392 Bone Fractures Diseases 0.000 claims 1
- 206010058019 Cancer Pain Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- 102220562239 Disintegrin and metalloproteinase domain-containing protein 11_F16P_mutation Human genes 0.000 claims 1
- 201000009273 Endometriosis Diseases 0.000 claims 1
- 206010017076 Fracture Diseases 0.000 claims 1
- 201000010915 Glioblastoma multiforme Diseases 0.000 claims 1
- 206010020880 Hypertrophy Diseases 0.000 claims 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010065390 Inflammatory pain Diseases 0.000 claims 1
- 208000002260 Keloid Diseases 0.000 claims 1
- 206010023330 Keloid scar Diseases 0.000 claims 1
- 102220475874 Keratin, type I cytoskeletal 10_L17A_mutation Human genes 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010033701 Papillary thyroid cancer Diseases 0.000 claims 1
- 208000000450 Pelvic Pain Diseases 0.000 claims 1
- 206010036805 Progressive massive fibrosis Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000003782 Raynaud disease Diseases 0.000 claims 1
- 208000012322 Raynaud phenomenon Diseases 0.000 claims 1
- 206010038748 Restrictive cardiomyopathy Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 208000034189 Sclerosis Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 1
- 206010042953 Systemic sclerosis Diseases 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 230000001746 atrial effect Effects 0.000 claims 1
- 210000000013 bile duct Anatomy 0.000 claims 1
- 102220350425 c.28T>C Human genes 0.000 claims 1
- 210000002808 connective tissue Anatomy 0.000 claims 1
- 230000006806 disease prevention Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 201000010048 endomyocardial fibrosis Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 239000003102 growth factor Substances 0.000 claims 1
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 1
- 210000001117 keloid Anatomy 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 201000003445 large cell neuroendocrine carcinoma Diseases 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 206010028537 myelofibrosis Diseases 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 201000007094 prostatitis Diseases 0.000 claims 1
- 230000026749 regulation of bone remodeling Effects 0.000 claims 1
- 230000037390 scarring Effects 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
- 150000003384 small molecules Chemical class 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 208000030045 thyroid gland papillary carcinoma Diseases 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910464016.0 | 2019-05-30 | ||
| CN201910464016 | 2019-05-30 | ||
| PCT/CN2020/092766 WO2020238998A1 (en) | 2019-05-30 | 2020-05-28 | Anti-trka antibodies and uses thereof |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022533855A JP2022533855A (ja) | 2022-07-26 |
| JPWO2020238998A5 true JPWO2020238998A5 (https=) | 2022-08-02 |
| JP2022533855A5 JP2022533855A5 (https=) | 2022-08-02 |
| JP7671699B2 JP7671699B2 (ja) | 2025-05-02 |
Family
ID=73506735
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021569941A Active JP7671699B2 (ja) | 2019-05-30 | 2020-05-28 | 抗ＴｒｋＡ抗体及びその使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20220204630A1 (https=) |
| EP (1) | EP3976657A4 (https=) |
| JP (1) | JP7671699B2 (https=) |
| CN (2) | CN114230663B (https=) |
| AU (1) | AU2020281378B2 (https=) |
| TW (1) | TWI908724B (https=) |
| WO (1) | WO2020238998A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230357411A1 (en) * | 2020-11-20 | 2023-11-09 | Sunshine Lake Pharma Co., Ltd. | Humanized anti-trka antibodies and uses thereof |
| CN112961244B (zh) * | 2021-02-28 | 2023-08-29 | 熙源安健医药（上海）有限公司 | 抗TrkA抗体或其抗原结合片段、其制备方法和应用 |
| EP4457246A4 (en) * | 2021-12-28 | 2025-11-19 | 4B Tech Suzhou Limited | TRKA ANTIBODIES AND THEIR APPLICATION |
| CN115611985A (zh) * | 2022-10-27 | 2023-01-17 | 合肥天港免疫药物有限公司 | 抗cd3的抗体及其应用 |
| EP4676499A2 (en) * | 2023-03-10 | 2026-01-14 | The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone | Methods and compositions for cellular immunotherapy- fib4 |
| US20250122291A1 (en) | 2023-10-13 | 2025-04-17 | Cephalon Llc | Anti-trka antibodies and uses thereof |
| CN120360963B (zh) * | 2025-04-23 | 2026-02-27 | 广州芬瑞生物科技有限公司 | 干细胞外泌体制备方法及该方法制备的外泌体在治疗男性勃起功能障碍中的用途 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6833268B1 (en) * | 1999-06-10 | 2004-12-21 | Abgenix, Inc. | Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions |
| GB0326780D0 (en) * | 2003-11-18 | 2003-12-24 | Imp College Innovations Ltd | Biological materials and uses thereof |
| US8911726B2 (en) * | 2004-09-22 | 2014-12-16 | Kyowa Hakko Kirin Co., Ltd | Stabilized human Igg4 antibodies |
| ITRM20050290A1 (it) * | 2005-06-07 | 2006-12-08 | Lay Line Genomics Spa | Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato. |
| US9751947B2 (en) * | 2008-02-04 | 2017-09-05 | Lay Line Genomics S.P.A. | Antibodies and derivatives thereof |
| US8183346B2 (en) * | 2008-12-05 | 2012-05-22 | Eli Lilly And Company | Anti-ferroportin 1 monoclonal antibodies and uses thereof |
| WO2013055809A1 (en) * | 2011-10-10 | 2013-04-18 | Xencor, Inc. | A method for purifying antibodies |
| AP2014008145A0 (en) * | 2012-06-08 | 2014-12-31 | Glenmark Pharmaceuticals Sa | Humanized anti-trkA antibodies with animo acid substitutions |
| EP2674439B1 (en) * | 2012-06-13 | 2017-02-01 | Rottapharm Biotech S.r.l. | Anti-TrkA antibodies, derivatives and uses thereof |
| MA41097A (fr) * | 2014-12-05 | 2017-10-10 | Glenmark Pharmaceuticals Sa | Anticorps anti-trka à propriétés inhibitrices améliorées et dérivés desdits anticorps destinés à être utilisés pour traiter les douleurs osseuses |
| WO2018042018A2 (en) * | 2016-09-02 | 2018-03-08 | European Molecular Biology Laboratory | Irradiation treatment of neurological sensations by photoablation |
| EP4470551A3 (en) * | 2017-03-14 | 2025-02-26 | Sunshine Lake Pharma Co., Ltd. | Dual-target fusion proteins comprising the fc portion of an immunoglobulin |
-
2020
- 2020-05-28 CN CN202111390356.7A patent/CN114230663B/zh active Active
- 2020-05-28 CN CN202010465851.9A patent/CN112010978B/zh active Active
- 2020-05-28 WO PCT/CN2020/092766 patent/WO2020238998A1/en not_active Ceased
- 2020-05-28 JP JP2021569941A patent/JP7671699B2/ja active Active
- 2020-05-28 EP EP20814249.7A patent/EP3976657A4/en active Pending
- 2020-05-28 AU AU2020281378A patent/AU2020281378B2/en active Active
- 2020-05-28 US US17/604,728 patent/US20220204630A1/en active Pending
- 2020-05-29 TW TW109118203A patent/TWI908724B/zh active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7840836B2 (ja) | 改善された血清アルブミン結合性免疫グロブリン可変ドメイン | |
| JP7628996B2 (ja) | 改善された血清アルブミン結合剤 | |
| JP2022533855A5 (https=) | ||
| JP7041516B2 (ja) | 共通軽鎖を有する二重特異性抗体又は抗体混合物 | |
| JP7417421B2 (ja) | 改善された血清アルブミン結合性免疫グロブリン単一可変ドメイン | |
| JP2025024012A (ja) | 改善された血清アルブミン結合剤 | |
| EP3689370B1 (en) | Anti-gdf15 antibodies | |
| JP6779252B2 (ja) | ＩＬ−１βへの結合メンバー | |
| JP7533897B2 (ja) | 融合タンパク質およびその使用 | |
| US20170342148A1 (en) | Anti il-34 antibodies | |
| AU2019236822B2 (en) | GIPR antibody and GLP-1 fusion protein thereof, and pharmaceutical composition and application thereof | |
| JP2019505565A5 (https=) | ||
| CN107074963A (zh) | 抑制血管内皮脂肪酶的酶活性的人源化单克隆抗体 | |
| JPWO2020238998A5 (https=) | ||
| CN110402254B (zh) | 针对fgfr1的单克隆抗体 | |
| CN113444176B (zh) | Ngf的抗体及其应用 | |
| CN102863533B (zh) | 抗体人源化改造方法 | |
| WO2018095932A1 (en) | Monoclonal antibody directed to fgfr1 | |
| CN114516917B (zh) | 人源化抗TrkA的抗体及其应用 | |
| CN107118273B (zh) | 一种全人源抗补体因子h的抗体 | |
| TW202233683A (zh) | 針對wnt受體ryk之抗體變異體 | |
| RU2800370C2 (ru) | Антитело к gipr и его слитый с glp-1 белок, а также фармацевтическая композиция на его основе и его применение | |
| HK40117444A (en) | Improved serum albumin binders | |
| JP2025503789A (ja) | 抗成長分化因子１５の抗体分子及びその応用 | |
| JPWO2022105814A5 (https=) |